Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.67% | -4.12% | |||
| Total Other Revenue | -21.56% | 16.70% | |||
| Total Revenue | -2.42% | -3.47% | |||
| Cost of Revenue | -2.94% | 0.20% | |||
| Gross Profit | -2.25% | -4.67% | |||
| SG&A Expenses | -8.70% | 4.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -77.89% | 171.43% | |||
| Total Operating Expenses | -6.03% | 2.37% | |||
| Operating Income | 6.93% | -15.92% | |||
| Income Before Tax | 19.30% | -23.31% | |||
| Income Tax Expenses | -16.09% | 206.02% | |||
| Earnings from Continuing Operations | 31.28% | -38.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 350.00% | |||
| Net Income | 31.01% | -38.67% | |||
| EBIT | 6.93% | -15.92% | |||
| EBITDA | 5.69% | -14.18% | |||
| EPS Basic | 31.28% | -38.25% | |||
| Normalized Basic EPS | 8.23% | -17.86% | |||
| EPS Diluted | 32.16% | -38.19% | |||
| Normalized Diluted EPS | 8.73% | -17.95% | |||
| Average Basic Shares Outstanding | -0.21% | -0.67% | |||
| Average Diluted Shares Outstanding | -0.67% | -0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||